Publications by authors named "Yirui Zhai"
Background: The ADAURA study indicated that adjuvant TKI therapy improves survival in postoperative patients with EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC), especially in stage III disease. However, the effect of PORT for stage III (N2) NSCLC with different EGFR statuses remains unclear, which we aimed to investigate in the present study.
Methods: Between 2006 and 2019, consecutive patients with pN2 non-squamous cell NSCLC (Nsq-NSCLC) after complete resection and adjuvant chemotherapy or EGFR tyrosine kinase inhibitor (TKI) who had detection of EGFR status were retrospectively analyzed.
Background & Aims: Portal and hepatic vein tumor thrombosis is associated with inferior outcomes in patients with hepatocellular carcinoma (HCC), and systemic treatment alone is often insufficient. This phase II trial evaluated the efficacy and safety of combining sorafenib with radiotherapy in advanced HCC with thrombosis.
Methods: Registered at ClinicalTrials.
Purpose: The therapeutic advantage of postoperative radiation therapy (PORT) for non-small cell lung cancer (NSCLC) has not been shown to benefit overall survival (OS) according to two randomized controlled trials (RCTs), albeit an enhancement in locoregional-free survival was observed. We aimed to evaluate the relative influence of locoregional recurrence (LR) and distant metastasis (DM) on OS for patients with NSCLC after surgery.
Methods: This was a secondary analysis of PORT-C RCT.
Purpose: This study explored the effectiveness of a Problem-based Learning (PBL) teaching model on the WeChat public platform for radiation oncology residency training programs.
Materials And Methods: The WeChat PBL program was initiated in 2019. The study recruited student participants, on a voluntary basis, who were in their first and second years of standardized training in radiation oncology.
Background: Hippo-avoidance prophylactic cranial irradiation (HA-PCI) requires a hippocampal avoidance zone expanded from hippocampus to ensure dose fall-off and compensate for setup errors. Most studies recommend a 5-mm margin, while it could be optimized to a 2-mm expansion. Here, we showed the details of optimized HA-PCI for limited-stage small cell lung cancer (LS-SCLC).
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the combination of deep inspiratory breath-hold (DIBH) and volumetric modulated arc therapy (VMAT) for enhancing dosimetric outcomes in left-sided postmastectomy radiotherapy (PMRT) for breast cancer patients.
- Results showed that DIBH significantly reduced radiation doses to the heart, left anterior descending artery (LAD), and left lung compared to free breathing (FB), ensuring better cardiopulmonary protection regardless of whether internal mammary node irradiation (IMNI) was included.
- The treatment's setup was highly precise, with setup errors of less than 0.3 cm and overall planning target volume margins under 1.0 cm
Article Synopsis
- The study looked at how radiotherapy (RT) helps people with diffuse large B-cell lymphoma (DLBCL) live longer without their cancer getting worse.
- Researchers compared different treatments and found a connection between how long patients lived without cancer (PFS) and overall survival (OS).
- They discovered that adding RT to chemotherapy helped patients live longer, especially those with more serious cases, and suggested this info can help with treatment decisions.
Article Synopsis
- Oncoplastic breast-conserving surgery (OBCS) enhances patient satisfaction despite potential cosmetic challenges, but complicates tumor location identification for follow-up radiation treatment; the study introduces a novel approach of giving a radiation boost before surgery instead of after.* -
- A phase II study involved 36 patients younger than 55 with early-stage breast cancer, who received a single dose of preoperative radiation to the tumor site followed by surgery and a shorter course of postoperative whole-breast radiation.* -
- Results showed a 19.4% rate of surgical complications, with most patients beginning their subsequent radiation treatment within the expected timeline, but some experienced mild skin reactions post-radiation.*
Article Synopsis
- Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with poor patient survival despite treatment advances.
- High levels of spindle apparatus coiled-coil protein 1 (SPDL1) in HCC tissues promote tumor cell growth and migration, while silencing SPDL1 induces cell death.
- The study identifies farnesyltransferase-beta (FNTB) as a key protein affected by SPDL1, suggesting that targeting the SPDL1/FNTB axis could be a promising approach for HCC treatment.
Article Synopsis
- The study assessed the outcomes of patients with hepatocellular carcinoma (HCC) who had tumor thrombus in the hepatic vein or inferior vena cava and received radiotherapy along with other systemic treatments.* -
- A total of 34 patients were analyzed, with a majority receiving targeted therapy; the results showed a high objective response rate of 79.4% and overall survival rates of 77.6% after one year and 36.3% after two years.* -
- Key findings indicated that higher levels of alpha-fetoprotein were linked to worse survival, while positive responses to treatment improved survival rates; the treatment was found to be safe, with no cases of radiation-induced liver disease.*
Introduction: The estimated dose of radiation to immune cells (EDRIC) has been shown to correlate with the overall survival (OS) of patients who receive definitive thoracic radiotherapy. However, the planning target volume (PTV) may be a confounding factor. We assessed the prognostic value of EDRIC for non-small cell lung cancer (NSCLC) in patients who underwent postoperative radiotherapy (PORT) with homogeneous PTV.
View Article and Find Full Text PDFBackground: This study aimed to evaluate the efficiency of hippocampal avoidance whole-brain radiotherapy with a simultaneous integrated boost (HA-WBRT-SIB) treating brain metastases (BM) and utility of the Hopkins Verbal Learning Test-Revised (HVLT-R) (Chinese version) in Chinese lung cancer patients.
Methods: Lung cancer patients with BM undergone HA-WBRT-SIB at our center were enrolled. Brain magnetic resonance imaging, The HVLT total learning score, and side effects were evaluated before radiotherapy and 1, 3, 6, and 12 months after radiotherapy.
Article Synopsis
- The study investigates the effectiveness of postoperative radiotherapy (PORT) for patients with non-small cell lung cancer (NSCLC) and aims to identify specific patients who might benefit from it.
- A radiomic prognostic index (RPI) based on texture features from preoperative chest CT scans was created, and a lymph-radiomic prognostic index (LRPI) was established by combining RPI with the number of positive lymph nodes.
- Results reveal that patients categorized as moderate-risk (based on the LRPI) saw improved overall survival with PORT, while low-risk and high-risk patients did not benefit, indicating the potential to tailor treatment based on individual risk assessment.
This study was to report proxy measures for mortality risk in patients with hematological malignancies across 185 countries globally and explore its association with their socioeconomic status and treatment. The incidence, mortality, and 5-year prevalence data were extracted from the GLOBOCAN database. The data regarding the human development index (HDI), gross national income (GNI), vulnerability index, and concordance with cancer Essential Medicines List (EML) were obtained from open-source reports.
View Article and Find Full Text PDFThe disease failure patterns and optimal treatment of bronchus-associated lymphoid tissue (BALT) lymphoma are unknown. This retrospective study involved 71 patients with primary BALT lymphoma who had received radiotherapy (RT), surgery, immunochemotherapy (IC), or observation. The median follow-up time was 66 months.
View Article and Find Full Text PDFBackground: Scarce evidence exists for clinical target volume (CTV) definitions of regional lymph nodes (LNs) in intrahepatic cholangiocarcinoma (iCCA) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA). We investigated the mapping pattern of nodal recurrence after surgery for iCCA and cHCC-CCA and provided evidence for the nodal CTV definition.
Methods: We retrospectively reviewed the medical records of patients with iCCA or cHCC-CCA who underwent surgery between 2010 and 2020.
Objectives: To investigate the prognostic capacity of baseline F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in extranodal natural killer/T-cell lymphoma (ENKTCL), and the influence of relative thresholds (RT) and absolute thresholds (AT) selection on prognostic capacity.
Materials And Methods: Metabolic tumor volume (MTV)-based parameters were defined using RTs (41 % or 25 % of maximum standardized uptake value [SUVmax]), ATs (SUV 2.5, 3.
This study aimed to predict the 5-year overall survival (OS) benefit of pola-R-CHP versus R-CHOP in the POLARIX trial based on the 2-year event-free survival (EFS) and progression-free survival (PFS) rates in diffuse large B-cell lymphoma (DLBCL). We identified randomized controlled trials (RCT) published before 31 May 2023. The correlation between the logarithmic (log) hazard ratio (HR) for EFS (HR) or PFS (HR) and the HR for OS (HR) was estimated at the trial-level.
View Article and Find Full Text PDFBackground: We aimed to investigate the incidence of lymphoma-related death (LRD) and the long-term net survival benefit of radiotherapy (RT) for early-stage diffuse large B-cell lymphoma (DLBCL) in the rituximab era.
Methods: 10,841 adults diagnosed with early-stage DLBCL between 2002-2015 were retrospectively analyzed using data from the Surveillance, Epidemiology, and End Results database. Primary therapy was categorized into combined-modality treatment (CMT, n = 3,631) and chemotherapy alone (n = 7,210).
Background: Radiotherapy-induced esophagitis (RE) diminishes the quality of life and interrupts treatment in patients with non-small cell lung cancer (NSCLC) undergoing postoperative radiotherapy. Dosimetric models showed limited capability in predicting RE. We aimed to develop dosiomic models to predict RE.
View Article and Find Full Text PDFImportance: Double-agent intravenous chemotherapy concurrent with radiotherapy is the standard of care for patients with inoperable esophageal cancer. However, patients tend to tolerate intravenous chemotherapy less well with age and comorbidities. It is essential to find a better treatment modality that improves survival outcomes without reducing the quality of life.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how heart and lung doses during postoperative radiation therapy (PORT) affect overall survival in patients with non-small cell lung cancer (NSCLC).
- A retrospective analysis of 307 patients reveals that higher heart doses correlate with poorer long-term survival outcomes, while higher lung doses are linked to reduced survival in the early stages.
- Results highlight the importance of minimizing radiation exposure to the heart and lungs to improve survival rates in NSCLC patients after PORT.
Purpose: Our objective was to assess the incidence and dose-volume predictors of radiation esophagitis (RE) in patients with breast cancer undergoing hypofractionated regional nodal irradiation.
Methods And Materials: Eligible patients who received intensity modulated radiation therapy (RT) at the chest wall, the supraclavicular/infraclavicular fossa, level II axilla, and/or the internal mammary chain after mastectomy were included. The prescribed dose was 43.
Background: Concurrent or definitive chemoradiotherapy is the standard treatment of locally advanced esophageal squamous cell carcinoma (ESCC). Elderly patients could not tolerate the standard concurrent chemotherapy and were treated with radiotherapy because of weak physical status and multiple comorbidities.
Objective: The efficacy and safety profile of concurrent (chemo) radiotherapy combined with nimotuzumab in elderly patients with ESCC were investigated.
Background: Significant progress has been made in the investigation of neoadjuvant immune-chemoradiotherapy (NICRT) and neoadjuvant immune-chemotherapy (NICT) on the outcomes of esophageal cancer patients. To summarize the current developments, a systematic review and meta-analysis were conducted to evaluate the efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy.
Methods: A search strategy of prospective studies on esophageal cancer receiving neoadjuvant immunotherapy was predefined to scan PubMed, Embase, Cochrane, and additional major conferences for prospective studies.